BeOne Medicines AG
ONC
NASDAQ·Healthcare·Biotechnology·Mkt cap $38.7B
$361.78
▲ +0.87%
P/E
6.67
Mkt Cap
$38.7B
52-Wk Range
$253.95–$385.22
52-Week Range
$253.95 - $385.22
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 7.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
2 risks
- Low volatility (beta 0.5).
- High premium - requires strong execution
Growth
Strong growth ahead
Value
High premium - requires strong execution
Momentum
Hot
+29.7% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ONC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 5, 2026
Reported EPS of $2.05 vs $1.66 consensus (+23.5% surprise). Revenue of $1.7B vs $1.6B expected (+5.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+23.5%
Revenue trend · last 2Q
—
+30%
Q1 26
Q2 26
$1.5B
$1.7B
Margins · last 2Q
Gross
89.8%
Operating
19.1%
Profit
13.9%
Wall Street consensus
9 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Wolfe Research · Aug 10, 2026
vs Industry
How ONC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.